Stay on forever or quit cold — that's how the long-term GLP-1 question usually gets framed. But there's a third path between those extremes, and it now has real trial evidence behind it.
Three different long-term paths, not two
When people think about the long-term future of GLP-1 treatment, the framing is often binary: stay on your current dose indefinitely, or stop entirely. There's a meaningful third option worth understanding — tapering to a lower, still-active maintenance dose rather than either extreme. Our discussion guide on talking to your doctor about stopping or tapering treatment covers how to raise this conversation; this guide covers how the dosing side of that decision actually works.
What the research suggests about dose reduction vs. stopping
According to PubMed, a 2026 clinical trial (SURMOUNT-MAINTAIN) directly compared continuing tirzepatide at its full effective dose, reducing to a lower dose, or switching to placebo after an initial weight-loss period. Both continuing at the full dose and reducing to a lower dose maintained significantly more weight loss than switching to placebo, though the full dose maintained somewhat more than the reduced dose (see our guide on the history of GLP-1 medications for more on this trial). This is meaningful evidence that a reduced maintenance dose is a genuine middle path — better than stopping, if a full dose isn't necessary or desired long-term.
Why someone might choose to taper rather than stay at full dose or stop
- Reaching a goal weight or body composition and wanting to shift from active weight loss to long-term maintenance, where a lower dose may be sufficient to hold results.
- Side effect burden that's worth trading some effect for improved day-to-day comfort, without giving up the medication's benefit entirely.